Abstract
Phase II clinical trials are commonly conducted as pilot studies to evaluate the efficacy and safety of the investigational drug in the targeted patient population with the disease or condition to be treated or prevented. When designing such a trial considering efficacy conclusions, people naturally think as follows: if efficacy evidence is very strong, a go decision should be made; if efficacy evidence is very weak, a no-go decision should be made; if the efficacy evidence is neither strong nor weak, no decision can be made (inconclusive). The designs presented in this paper match this natural thinking process with go/no-go/inconclusive outcomes. Both two-/three-stage designs are developed with three outcomes. Additionally, a general approach based on conditional error function is implemented such that new decision boundaries can be calculated to handle mid-course sample size change which results in either ‘over-running’ or ‘under-running’ and ensure the control of overall type I error. A free open-source R package tsdf that calculates the proposed two-/three-stage designs is available on CRAN.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.